J Cancer 2019; 10(18):4196-4207. doi:10.7150/jca.34145 This issue
1. Department of Pathology, Medical School of Southeast University, Nanjing 210009, China
2. Zibo Vocational Institute, Zibo 255314, China
3. Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA
4. Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
#: These authors contributed equally to this article.
Purpose: Yes-associated protein 1 (YAP1) is overexpressed in head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether verteporfin, a YAP1 inhibitor, can inhibit HNSCC cells as well as the molecular mechanisms involved.
Methods: YAP1 expression was investigated by immunohistochemistry in human head and neck carcinoma tissues (n=70). CCK-8 assay, colony formation assay, flow cytometric analysis, wound-healing assay and Transwell migration and invasion assays were used to evaluated the effects of verteporfin on the six HNSCC cell lines (three HPV-positive and three HPV-negative). The transcription and protein expression levels of YAP1 and its associated genes were investigated by real-time PCR and Western blotting, respectively. The effects of verteporfin on HNSCC cells in vivo were assessed by a xenograft model.
Results: YAP1 expression was significantly higher in carcinoma tissues than in tumor-adjacent normal tissues (n=10). A CCK-8 assay showed that the inhibitory effects of verteporfin on HNSCC cells were markedly enhanced by light activation. Verteporfin significantly inhibited HNSCC cell proliferation, migration and invasion, induced apoptosis, and arrested the cell cycle at the S/G2 phase. Verteporfin significantly attenuated the expression of genes related to epithelial-mesenchymal transition (YAP1, Snail, CTNNB1 and EGFR) and stemness (Oct4 and YAP1) and increased E-cadherin expression in HNSCC cells. Furthermore, verteporfin significantly inhibited PD-L1 expression in HNSCC cells. However, the expression levels of HPV-16 E6 and E7 did not change with VP treatment. The anticancer effect of verteporfin on HNSCC was confirmed by the inhibition of xenograft growth in vivo.
Conclusions: Our results indicate that YAP1 overexpression is involved in HNSCC tumorigenesis and verteporfin is a potential therapeutic drug for HNSCC.
Keywords: Verteporfin, YAP1, Head & neck squamous cell carcinoma, Cell proliferation, Epithelial-mesenchymal transition, Stemness
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide . Recent studies have shown that more than 20% of HNSCCs contain human papillomavirus (HPV) DNA, especially that of HPV-16, in which E6 and E7 are major viral oncoproteins . HPV-positive and -negative HNSCCs represent different clinicopathological and molecular entities, and HPV-positive HNSCC patients have a better prognosis [3, 4]. Because of the anatomical structures involved and the importance of organ function, HNSCC treatment is complicated, and the 5-year survival rate of patients has not improved significantly . Therefore, identifying new drugs and therapeutic approaches is required to improve the outcome of HNSCC therapy.
The Hippo pathway is an evolutionarily conserved signaling pathway regulating numerous biological processes, including cell growth, organ size, and tissue homeostasis. This pathway consists primarily of upstream signals, core kinases (MST1/2 and LATS1/2) and downstream effectors, including the transcriptional coactivators Yes-associated protein (YAP) and TAZ, which mainly interact with TEA domain (TEAD) family transcription factors (TFs) to regulate cell proliferation, survival, migration, stemness, epithelial-mesenchymal transition (EMT) and differentiation . The YAP gene encodes two major isoforms YAP1 and YAP2, which contain one WW domain and two WW domains, respectively.
Dysregulation of the Hippo pathway has been implicated in many human diseases, including cancer [6, 7]. As a key component of the Hippo pathway, YAP has been found to be overexpressed in many human cancers, including HNSCCs [8-10]. Therefore, YAP is an attractive therapeutic target in cancer. Verteporfin (VP), a YAP inhibitor, is FDA-approved for use with photodynamic therapy to treat age-related macular degeneration. VP has been recently proven to be an inhibitor of YAP-TEAD complex and preventing YAP-induced oncogenic growth . Recently, the anticancer activity of VP has been reported in various cancers, such as ovarian , colon , pancreatic  and thyroid  cancers. However, the effects of VP on HNSCC cells have seldom been reported and the anticancer mechanisms of VP are poorly understood. In this study, we aimed to investigate the effects of VP on cell proliferation, apoptosis, migration, invasion and the expression of certain key genes involved in the molecular biology of HNSCC and to assess the effects of VP on HNSCC cell xenografts.
The human head and neck carcinoma and normal tissue array, with stage and grade information, were purchased from Outdo Biotech Inc. (Shanghai, China). This array contained 70 carcinoma tissues and 10 tumor-adjacent normal tissues. The study was approved by the ethics committee of the Southeast University.
YAP1 protein expression in human head and neck tissues was detected by using peroxidase-based immunohistochemistry (IHC). In brief, formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and hydrated through descending concentrations of ethanol before being placed in blocking solution to inhibit endogenous peroxidase activity. The slides were incubated with primary antibody (1:200 dilution; Cell Signaling Technology, MA, USA) at 4°C overnight. A horseradish peroxidase-conjugated rabbit secondary antibody (1:4000 dilution; Proteintech, Rosemont, USA) was added for 60 min at room temperature, followed by 3,3′-diaminobenzidine kit (DAB, Invitrogen, Carlsbad, CA) for staining. Sections were scanned with an iSCAN Coreo slide scanner (3D-Histech, Pannoramic, Hungary). Positive YAP1 staining was defined as brown granules in the cytoplasm or nuclei. The intensity score was graded as follows: - (negative), + (low), ++ (moderate), and +++ (high). The results were evaluated by two independent pathologists.
The sources and characteristics of the HPV-negative HNSCC cell lines SCC-4, CAL-27 and SCC-25 and the HPV 16-positive HNSCC cell lines UM-SCC-47, UPCI-SCC-090, and 93-VU-147T have been described in a previous publication . UM-SCC-47, UPCI-SCC-090 and 93-VU-147T cells were cultured in high glucose Dulbecco's Modified Eagle's Medium (H-DMEM) (HyClone). SCC-4, SCC-25 and CAL-27 cells were cultured in DMEM/F-12 (HyClone). All media were supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco-BRL), 100 units/ml penicillin and 100 μg/ml streptomycin (Beyotime Institute of Biotechnology, Shanghai, China).
VP (Selleck Chemicals, S1786) was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at a concentration of 10 mg/mL and stored at -80°C. During treatment, the stock solution was diluted to the required concentration using cell culture medium to yield the working solution in the dark.
The effects of VP on the proliferation of cancer cells were assessed using a CCK-8 kit (Beyotime) according to the manufacturer's manual, with or without light activation. Briefly, 2 × 103 cells/well were seeded in 96-well plates, and allowed to attach overnight. Then the medium was replaced with fresh cell culture medium supplemented with various concentrations of VP and incubated in the dark. After 12 h, photoactivation was performed in the light-activated groups with a light (Philips three-base color straight fluorescent lamp, 14 watts) for 20 min, afterwords cells were cultured in a 37°C incubator. The groups without light activation were constantly maintained in the dark. Each group included six replicates.
The optical density (OD) at 450 nm was measured using a microplate reader (BioTek) at 24, 48 and 72 h. Cell viability was calculated as follows: Cell viability (%) = ODtreated group mean/ODcontrol group mean × 100.
In the subsequent experiments, VP treatment was performed with light activation.
An apoptosis kit (MultiSciences Biotech, Hangzhou, China) and a cell cycle kit (Beyotime) were used according to the manufacturers' manuals. In the apoptosis assay, the cells were seeded in 6-well plates and VP treatment was as CCK-8 assay. After VP light activation for 24 h, the cells were harvested and washed twice with cold phosphate buffer saline (PBS) and stained with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) in the dark at room temperature for for 15 min. In the cell cycle assay, the cells were seeded in 6-well plates using non-serum cell culture medium for 12 h. Then the cells were treated with VP as CCK-8 assay. After VP light activation for 24 h, the cells were harvested, fixed in 70% ethanol at 4°C overnight, and then stained with PI at 4°C for 30 min in the dark. Stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences).
The cells (1 × 103 cells/well) were plated in 6-well plates and allowed to attach overnight. Then the medium was replaced with fresh medium with VP for 12 h. Then, the cells were irradiated with the light for 20 min to activate the VP. The fresh medium was changed every three days. At 10 days, the cells were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet for 30 min. The cell colonies were imaged, and the number of colonies was counted for statistical analysis.
For the wound-healing assay, cells were grown to confluence and treated with VP in the dark. After 12 h, the cells were irradiated with the light to activate VP. Next, the cell layer was scratched along the central axis using a sterile plastic tip, and the fresh medium was changed. The degree of cell migration at 24 h was calculated as follows: (Distance of cell migration at 24 h/width of scratch at 0 h) × 100%.
Transwell assay was used to assess the cell migration and invasive abilities. Briefly, after VP light activation, HNSCC cells (5 × 104) were suspended in 0.1 mL of medium without FBS and seeded into the upper chambers of Matrigel-coated (BD Biosciences, Bedford, MA) (for assessing the cell invasion ability) or uncoated (for assessing the cell migration ability) polycarbonate membrane filters. Then, medium containing 10% FBS was added to the lower chambers as a chemoattractant. Cells that had migrated to the lower chambers at 24 h were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet for 30 min. Three low-magnification areas were randomly selected, and the number of migrated cells was counted.
The cells were seeded in 6-well plates using cell culture medium for 12 h. Then the cells were treated with VP in dark. After 12 h, the cells were irradiated with the light to activate VP. The cells were harvested after treatment with light activated VP for 12 h. Total RNA was extracted from cells using the RNAiso Plus (TAKARA Biotechnology, Dalian, China) according to the manufacturer's instructions. RT-qPCR was performed using a SYBR-Green-based PCR kit (TAKARA) with an Applied Biosystems StepOnePlus Real-Time PCR system (ABI, Foster City, CA, USA). The comparative Ct method was applied to determine the fold-differences in expression levels relative to those in β-actin. The primers used are listed in Table 1.
The primers of RT-qPCR
|Gene||Forward (5ʹ-3ʹ)||Reverse (5ʹ-3ʹ)|
The cells were prepared and treated with VP as RT-qPCR above. After VP light activation for 6 h or 12 h, total protein was extracted from cells for Western blot analysis as described previously . Antibodies against YAP1 (1:2000 dilution), E-cadherin (1:1000 dilution), Snail (1:1000 dilution), β-catenin (1:2000 dilution), EGFR (1:4000 dilution), programmed death ligand-1 (PD-L1) (1:1000 dilution), Twist1 (1:1000 dilution) and β-actin (1:4000 dilution) were obtained from Proteintech. An antibody against Oct4 (1:1000 dilution) was obtained from BioSS. Antibodies against HPV-16 E6 (1:1000 dilution) and E7 (1:200 dilution) were obtained from Abcam (Cambridge, UK) and Santa Cruz (CA, USA), respectively. A horseradish peroxidase-linked secondary antibody (1:4000 dilution) was obtained from Proteintech.
Six-week-old SCID mice (BALB/c) were handled according to the Guidelines for Animal Experiments of the Southeast University. Each of the nude mice was subcutaneously injected with 106 cells/100 μl as indicated in Fig. 7. When the tumor volume reached approximately 80 mm3, the mice were randomized to the different experimental groups (n=4, half male and half female). VP was injected intraperitoneally at a concentration of 100 mg/kg or the vehicle (control) every 2 days. Tumors were excised and weighed at 21 days. Tumor volume was calculated as the product of all three dimensions.
YAP1 expression in tissues and the expression levels of key proteins in HNSCC cells. (A) Representative images showing YAP1 protein expression in human head and neck carcinoma tissues and tumor-adjacent normal tissues as analyzed by IHC. (a, b) Tumor-adjacent normal tissue. - (no stain) (c, d) Well-differentiated squamous cell carcinoma. + (low stain) (e, f) Well-differentiated squamous cell carcinoma. ++ (moderate stain) (g, h) Moderately differentiated squamous cell carcinoma. +++ (high stain) (B) The expression levels of key proteins in HNSCC cells were measured by Western blotting in the steady-state growth.
All experiments were repeated at least twice. The data were analyzed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA) and SPSS 17.0 (SPSS Inc., Chicago, IL) and expressed as the mean values ± SEM (standard error of the mean). Statistical analysis was performed using the standard Student's t-test. The significance of data obtained from patient specimens was determined using a Chi-square test. P<0.05 was considered to indicate a significant difference (*P< 0.05, **P≤ 0.01, ***P≤ 0.001).
YAP1 protein expression was evaluated using IHC in head and neck carcinoma tissues and tumor-adjacent normal tissues. Representative results are shown in Fig. 1A. Our results show that YAP1 expression was significantly upregulated in carcinoma tissues compared to that in tumor-adjacent normal tissues (Table 2).
YAP1 expression in 70 head and neck carcinoma tissues and 10 tumor-adjacent normal tissues.
|- Number (%)||+ Number (%)||++ Number (%)||+++ Number (%)||P value*|
|Tumor-adjacent tissues||5 (50)||5 (50)||0 (0)||0|
|Carcinoma tissues||2 (2.9)||40 (57.1)||26 (37.1)||2 (2.9)||0.001|
*P value is determined by Chi-square test.
Fig. 1B shows the expression of key proteins in HNSCC cells in steady-state growth. YAP1 expression was non-significantly associated with HPV status, however, YAP1 expression in SCC-25 and UM-SCC-47 cell lines was higher than in the other HNSCC cell lines and YAP1 expression in 93-VU-147T cell line was lowest in the HNSCC cell lines tested. CDH1 (E-cadherin gene) expression was higher in UPCI-SCC-090 and 93-VU-147T cells than in the other HNSCC cell lines. Snail expression was high in all HNSCC cell lines except UPCI-SCC-090 cell line, suggesting that the Snail may inhibit E-cadherin expression in HNSCC cells and that the expression levels of E-cadherin and Snail are inversely related. These results suggest that SCC-4, SCC-25, CAL-27, UM-SCC-47 and 93-VU-147T cells are epithelial-like cells with partial EMT, while UPCI-SCC-090 cells still maintain epithelial properties. Oct4 expression was high in all HNSCC cell lines except UPCI-SCC-090 and 93-VU-147T cell lines, suggesting that these cell lines lack stemness. HPV-negative HNSCC cells had relatively higher levels of EGFR expression than HPV-positive HNSCC cells, consistent with our previous results . PD-L1 expression was higher in UPCI-SCC-090 and 93-VU-147T cell lines than in the other HNSCC cell lines. The transcription levels of key genes in HNSCC cells (Figure S1) were consistent with the protein levels.
Fig. 2 shows the effects of VP on the proliferation of HNSCC cells with or without light activation by CCK-8 assay. VP exhibited minimal cytotoxicity to HNSCC cells at low concentrations (0.5 μM-4 μM) but some cytotoxicity at high concentrations (4 μM-6 μM) without light activation (Fig. 2A). However, VP significantly inhibited the proliferation of HNSCC cells in a dose-dependent manner with light activation (Fig. 2B). Our results showed that the response of HPV-positive HNSCC cells to VP was not appreciably different from that of HPV-negative HNSCC cells (Fig. 2B).
The apoptosis assays showed that the percentages of apoptosis in control SCC-4, SCC-25, CAL-27, UM-SCC-47, UPCI-SCC-090 and 93-VU-147T cells were nearly 2.5%, 2.9%, 6.4%, 22.9%, 8.8% and 8.7%; these percentages increased to 12.9%, 15.1%, 52.4%, 26.9%, 61.4% and 18.9% after treatment with 1 μM VP for 24 h and increased further to 49.5%, 35.0%, 99.3%, 45.0%, 76.9% and 49.4%, respectively, after treatment with 2 μM VP for 24 h. Histogram analysis indicates that the apoptotic cells are significantly increased in the VP treated groups relative to the control (Fig. 3A).
Inhibitory effect of VP on the proliferation of HNSCC cells. Inhibitory effects of VP on the proliferation of HNSCC cells without light activation (A) and with light activation (B) using the CCK-8 assay. The means±SEMs of three independent experiments are shown. *P < 0.05, **P < 0.01, ***P < 0.001 by Student's t-test
VP induces apoptosis and G2 arrest in HNSCC cells. (A) Cells were cultured for 24 h after VP light activation, and the apoptosis rates were determined by flow cytometry. The experiment was performed in triplicate, and the data are presented as the means±SEMs. *P < 0.05, **P < 0.01, ***P < 0.001 by Student's t-test (B) Flow cytometry showed that HNSCC cell growth was inhibited in the G2 phase following exposure to light activated VP for 24 h. The experiment was performed in triplicate, and the data are presented as the means±SEMs.
Fig. 3B shows that under normal conditions, the cell cycle distribution was different among these cell lines. Generally, the percentage of cells in G1 phase was higher in HPV-negative HNSCC cells than in HPV-positive HNSCC cells. When DNA is damaged, the cell cycle is arrested at the G1/S checkpoint or G2/M checkpoint for DNA repair; alternatively, cells will undergo apoptosis if repair efforts fail. Fig. 3B shows the cell cycle distribution of HNSCC cells after treatment with 1 μM VP for 12 h. G2 phase arrest was observed in most cell lines except UPCI-SCC-090 and 93-VU-147T. UPCI-SCC-090 and 93-VU-147T cells were arrested at the G1/S phase transition and in G1 phase, respectively. A noticeable sub-G1 population (apoptotic cells) was observed in UPCI-SCC-090 and 93-VU-147T cells.
In the colony formation assay, equal numbers of viable HNSCC cells per well were seeded in 6-well culture plates before treatment with different concentrations of VP. The results showed that 0.25 μM and 0.5 μM VP significantly inhibited the colony forming capacity compared with DMSO treatment (Fig. 4).
The effect of VP on the migration of HNSCC cells was examined using the transwell migration assay. In the present study, the migration of cells treated with 0.25 and 0.5 µM VP was significantly decreased in a dose-dependent manner compared with the DMSO group cells (Fig. 5). Consistently, the results of the wound healing assay revealed that VP at concentrations of 0.25 µM and 0.5 µM significantly inhibited the migration of HNSCC cells compared with the DMSO group cells (Figure S2). Furthermore, the transwell invasion assays showed that cell invasion activity was significantly inhibited by VP in a dosage dependent manner (Fig. 5). These results clearly demonstrated that the HNSCC cell migration and invasion ability was inhibited by VP.
Inhibitory effects of VP on colony formation by HNSCC cells. After VP light activation, HNSCC cells were cultured for 10 days with the fresh medium. The data are presented as the means ± SEMs. ***P < 0.001 by Student's t-test
Inhibitory effects of VP on the migration and invasion of HNSCC cells. Cells were cultured for 24 h after VP light activation, and the extents of HNSCC cell migration and invasion were determined using a Transwell assay. The experiments were performed in triplicate, and the data are presented as the means±SEMs. ***P<0.001 by Student's t-test
Fig. 6 shows the effects of VP on key genes in HNSCC cells at the mRNA (Fig. 6A) and protein (Fig. 6B) levels. VP treatment significantly decreased the expression of YAP1, Snai1, CTNNB1 (β-catenin gene), Oct4, EGFR and PD-L1, whereas the expression of E-cadherin was upregulated in HNSCC cells. Our results showed that the response of HPV-positive HNSCC cells to VP was generally similar to that of HPV-negative HNSCC cells except E-cadherin. E-cadherin expression in SCC-4, SCC-25 and CAL-27 cells was increased by approximately 12-, 10- and 7-folds, respectively, whereas E-cadherin expression in UM-SCC-47, UPCI-SCC-090 and 93-VU-147T cells was only increased by approximately 2-, 2- and 3-folds, respectively, after treatment with 1 μM VP for 12 h compared with the control. However, the expression levels of HPV-16 E6 and E7 did not change with VP treatment.
Effects of VP on mRNA and protein expression in HNSCC cells. (A) The transcription levels of key genes were assessed by RT-qPCR analysis of HNSCC cells treated with light activated VP for 12 h. The relative transcription levels of those genes were normalized to those of β-actin. The data are presented as the means ± SEMs. ***P < 0.001 by Student's t-test (B) The expression levels of key proteins were determined by Western blot analysis of HNSCC cells treated with light activated VP for 6 h and 12 h.
After treatment with VP for 21 days, VP treatment significantly inhibited tumor growth compared to that of control tumors (Fig. 7) and tumor volume (mm3) in the SCC-4, SCC-25, UM-SCC-47 and 93-VU-147T cell models was declined from 959, 563, 644, 783 in the control groups to 447, 186, 249, 286 in the VP groups, respectively. This inhibitory effect was no obviously difference between HPV-positive xenografts and HPV-negative xenografts, consistent with that YAP1 expression was not closely associated with HPV status in HNSCC cells (Fig. 1B).
The cBioPortal online analysis tool (cBioPortal for Cancer Genomics)  shows that YAP1 is frequently altered in different types of cancers according to data in The Cancer Genome Atlas (TCGA) database and head and neck carcinoma exhibits the second highest frequency of YAP1 gene alteration . Consistent with previous reports [17, 18], our results showed that YAP1 expression was significantly upregulated in head and neck carcinoma tissues compared to that in tumor-adjacent normal tissues, suggesting that YAP1 overexpression is involved in HNSCC tumorigenesis.
Inhibitory effects of VP on HNSCC cell xenograft growth. When the xenograft tumors attained a volume of ~80 mm3, the mice were treated with VP or vehicle every other day for 21 days by intraperitoneal injection. The tumor volumes and weights were determined after sacrifice. The data are presented as the means±SEMs. **P<0.01, ***P<0.001 by Student's t-test
The baseline expression levels of key genes differ among HNSCC cells (Fig. 1B), reflecting the different molecular characteristics of these cells. Our data showed that YAP1 expression was not appreciably different between HPV-positive and -negative HNSCC cells, consistent with previous reports [8, 19], suggesting that HPV oncoproteins may not influence YAP1 expression. Moreover, our data showed that YAP1 expression was highest in UM-SCC-47 cells, moderate in UPCI-SCC-090 cells and lowest in 93-VU-147T cells in the three HPV-positive HNSCC cell lines, consistent with a previous report, in which authors show that UM-SCC-47 cell line has YAP1 gene amplification and 93-VU-147T cell line has YAP1 gene deep deletion .
The anticancer effects of the photodynamic agent VP are reported to be different with light activation [12, 20, 21] and without light activation [22, 23]. Our data showed that VP exhibited minimal cytotoxicity to HNSCC cells at low concentrations (0.5 μM-4 μM) without light activation, whereas the cytotoxic effects of VP on HNSCC cells were significantly higher at the same concentrations with light activation, indicating that light-induced activation is required for VP cytotoxicity. Reactive oxygen species (ROS) generated upon light-induced activation may account for this cytotoxic effect after the cellular uptake of VP [20, 24]. Although we can't exclude the effect of ROS induced by VP after light activation on normal cells or tissues, in general normal cells may be capable of maintaining redox homeostasis under exogenous ROS  and tumor cells are more prone than normal cells to oxidative stress . Thus, our data suggest that light activation is necessary if VP is used in oncological therapy in the future.
Although differences in the cell cycle distribution between HPV-negative and -positive HNSCC cells were observed (Fig. 3B), the response of HPV-positive HNSCC cells to VP was not appreciably different from that of HPV-negative HNSCC cells. The only difference is that there was a sub-G1 peak in HPV-positive UPCI-SCC-090 and 93-VU-147T cells. The observed inhibitory effects of VP on HNSCCs are attributed to G2 or G1 phase arrest and apoptosis. Similar effects of VP have been reported, such as G1 phase arrest in pancreatic adenocarcinoma cells  and G2/S arrest in thyroid cancer cells .
The results of cell colony formation, migration and invasion assays showed that low concentrations of VP significantly inhibited the colony formation, migration and invasion of HNSCC cells, which indicates that VP inhibits EMT and stemness of HNSCC cells. Capacity of cell colony formation is generally considered to be associated with cancer stem-like cells, and the abilities of cell migration and invasion are considered to be linked to EMT. Previous studies have shown that VP can significantly inhibit cell adhesion and invasion of breast cancer cells  and reducing YAP protein suppresses migration and invasion of non-small cell lung cancer cells .
EMT and stemness are basic features of cancer stem cells, and YAP1 is involved in these processes . Our data showed that VP significantly attenuated the expression of genes related to EMT (YAP1, Snail, CTNNB1 and EGFR) and stemness (Oct4 and YAP1) and increased E-cadherin expression in HNSCC cells. The expression level of E-cadherin, a major interepithelial adhesion molecule, is closely related to EMT. Reduced or absent E-cadherin expression has been considered to be an initial step for the invasion and metastasis of many carcinoma cells . Snail has been demonstrated to repress the transcription of the CDH1 gene. The loss of E-cadherin expression was mostly caused by Snail expression in our study, since the Twist and Snail are the most commonly expressed TFs in HNSCC , and the expression levels of Twist1 were unchanged in HNSCC cells after treatment with VP when E-cadherin was upregulated (Figure S3). Although the expression of E-cadherin was higher in UPCI-SCC-090 and 93-VU-147T cells than in the other HPV-negative HNSCC cells in steady-state growth (Fig. 1B), suggesting that HPV oncoproteins may influence E-cadherin expression, Fig. 6B showed that the upregulation of E-cadherin expression was more obvious in HPV-negative HNSCC cells than in HPV-positive HNSCC cells after VP treatment, suggesting that VP may be a novel drug inhibiting the invasion and metastasis of HPV-negative HNSCC.
The expression of a stemness marker Oct4 in 93-VU-147T cell line was lowest among all HNSCC cell lines, suggesting that this cell line lacks cancer stemness. Consistent with this finding, previous reports have shown that 93-VU-147T cells are the most sensitive one of tested HNSCC cell lines to therapies [15,32]. Oct4 has been demonstrated to be a key regulator of stemness in HNSCC . YAP1 can regulate cancer cell EMT and stemness via the YAP1-Oct4-Sox2 signaling axis  by directly interacting with Oct4 through its WW domain . A previous study has reported that VP downregulates Oct4 expression in retinoblastoma cells .
β-Catenin plays two major roles in cells. In canonical Wnt/β-catenin signaling, it is the key effector responsible for transducing signals to the nucleus to trigger the expression of target genes, including genes orchestrating the EMT program. The second role of β-catenin is linked to E-cadherin in the formation of epithelial cell-cell adherens junctions. The triggering of EMT by β-catenin is well known . In fact, Hippo/YAP signaling exhibits multiple layers of interaction with Wnt/β-catenin signaling [37, 38], and both pathways cooperate to promote EMT and stemness. YAP has been reported to promote human glioma growth through partially enhancing Wnt/β-catenin signaling .
EGFR, a receptor tyrosine kinase, is of particular interest in HNSCC, as it is detectable in approximately 85% of HNSCCs . We found that the expression of EGFR seemed to be negatively associated with the expression of E-cadherin. The mechanism is somewhat complex and possibly operates through the activation of EGFR to decrease cell adhesion , or reduction of E-cadherin results in upregulation of EGFR transcription . EGFR signaling plays a significant role in EMT in HNSCC . Our data showed that VP inhibited EGFR expression, consistent with the results of Song et al. who showed that YAP1 induced EGFR transcription via a TEAD binding site in the EGFR promoter . They also found that VP great reduced xenograft growth of esophageal cancer JHESO cells, which express EGFR .
Our data showed that the expression of PD-L1, a ligand for the immune checkpoint protein programmed death 1 (PD1), was increased in UPCI-SCC-090 and 93-VU-147T cells, suggesting that HPV oncoproteins may influence PD-L1 expression in HPV-infected cells. The relationship between PD-L1 and HPV status in HNSCC is controversial. For example, Schoenfeld et al. reported that PD-L1 expression was associated with HPV status in oropharyngeal squamous cell carcinoma (OSCC) , whereas Kim et al. reported PD-L1 expression in the majority of OSCC patients regardless of HPV status . PD-L1 is physiologically expressed at low levels but can be highly expressed in neoplastic cells . PD-L1 gene amplification and PD-L1 protein expression have been reported to be common events in squamous cell carcinoma of the oral cavity . Therefore, inhibited or reduced PD-L1 expression on cancer cells facilitates T cell activation and ameliorates the immunosuppressive microenvironment. The PD1 inhibitors pembrolizumab and nivolumab are currently approved for HNSCC therapy, and the PD-L1 inhibitors durvalumab, atezolizumab and avelumab are under evaluation in HNSCC . Some researchers recently reported that YAP regulates PD-L1 expression via binding to the PD-L1 enhancer in lung cancer cells [49, 50]. Our data showed that VP significantly downregulated the expression of PD-L1 in HNSCC cells, consistent with the results of Hsu et al. who reported that PD-L1 expression was correlated with YAP expression and VP downregulated PD-L1 expression in human malignant pleural mesothelioma .
Additionally, we examined the effect of VP on the expression of the E6 and E7 oncogenes in three HPV-positive HNSCC cell lines. However, VP did not change the expression of E6 and E7, suggesting that the anticancer effects of VP are mediated through an E6 and E7-independent mechanism in HPV-positive HNSCC cells.
In conclusion, our results demonstrated that VP inhibited the proliferation of HNSCC cells both in vitro and in vivo, and the inhibitory effects of VP on HNSCC cells were significantly enhanced by light activation in vitro. The anticancer effects of VP on HNSCC cells are mediated via the attenuation of the expression of genes related to EMT and stemness and the increase of E-cadherin expression. Furthermore, VP significantly inhibited the expression of immunosuppressive protein PD-L1 in HNSCC cells. These data indicate that VP is a potential therapeutic drug for HNSCC.
DMSO: dimethyl sulfoxide; EGFR: epidermal growth factor receptor; EMT: epithelial-mesenchymal transition; HNSCC: head and neck squamous cell carcinoma; HPV: human papillomavirus; IHC: immunohistochemistry; Oct4: Octamer-binding protein 4; OSCC: oropharyngeal squamous cell carcinoma; PD1: programmed death 1; PD-L1: PD 1 ligand; ROS: reactive oxygen species; TEAD: TEA domain family transcription factors; TF: transcription factor; VP: verteporfin; YAP: Yes-associated protein.
This work was supported by grants from the National Natural Science Foundation of China (grant number 81602330), the Project of Shandong Province Higher Educational Science and Technology Program (No. J18KA299), Zibo key research and development plan (No. 2018kj010140) and the Natural Scientific Foundation of Shandong Province (grant number ZR2015PH056).
The authors have declared that no competing interest exists.
1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9-22
2. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15:6758-6762
3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35
4. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM. et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956
5. Guntinas-Lichius O, Wendt TG, Kornetzky N, Buentzel J, Esser D, Boger D. et al. Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry. Oral Oncol. 2014;50:1157-1164
6. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811-828
7. Pfleger CM. The Hippo Pathway: A master regulatory network important in development and dysregulated in disease. Curr Top Dev Biol. 2017;123:181-228
8. He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC. et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 2015;7:1426-1449
9. Guichet PO, Masliantsev K, Tachon G, Petropoulos C, Godet J, Larrieu D. et al. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence. J Pathol. 2018;246:205-216
10. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC. et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24:4232-4242
11. Feng J, Gou J, Jia J, Yi T, Cui T, Li Z. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9:5371-5381
12. Pellegrini P, Serviss JT, Lundback T, Bancaro N, Mazurkiewicz M, Kolosenko I. et al. A drug screening assay on cancer cells chronically adapted to acidosis. Cancer Cell Int. 2018;18:147
13. Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J. et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 2017;108:478-487
14. Liao T, Wei WJ, Wen D, Hu JQ, Wang Y, Ma B. et al. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J Cancer. 2018;9:1329-1336
15. Du S, Liu K, Gao P, Li Z, Zheng J. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status. Life Sci. 2018;212:182-193
16. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404
17. Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan KH. et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One. 2011;6:e27529
18. Eun YG, Lee D, Lee YC, Sohn BH, Kim EH, Yim SY. et al. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget. 2017;8:111130-111143
19. Cheng H, Yang X, Si H, Saleh AD, Xiao W, Coupar J. et al. Genomic and transcriptomic characterization links cell lines with aggressive head and neck cancers. Cell Rep. 2018;25:1332-1345
20. Belzacq AS, Jacotot E, Vieira HL, Mistro D, Granville DJ, Xie Z. et al. Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res. 2001;61:1260-1264
21. Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY. et al. Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood. 2000;95:256-262
22. Ma YW, Liu YZ, Pan JX. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res. 2016;6:2816-2830
23. Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW. et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014;124:67-73
24. Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN. et al. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem. 2011;286:7290-7300
25. Wang N, Wu Y, Bian J, Qian X, Lin H, Sun H. et al. Current development of ROS-Modulating agents as novel antitumor therapy. Curr Cancer Drug Targets. 2017;17:122-136
26. Suzuki-Karasaki Y, Fujiwara K, Saito K, Suzuki-Karasaki M, Ochiai T, Soma M. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization. Oncotarget. 2015;6:21572-21588
27. Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L. et al. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer Res. 2018;37:175
28. You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH. et al. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015;6:4357-4368
29. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23:785-793
30. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155-163
31. Goppel J, Mockelmann N, Munscher A, Sauter G, Schumacher U. Expression of epithelial-mesenchymal transition regulating transcription factors in head and neck squamous cell carcinomas. Anticancer Res. 2017;37:5435-5440
32. Arenz A, Ziemann F, Mayer C, Wittig A, Dreffke K, Preising S. et al. Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol. 2014;190:839-846
33. Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS. et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene. 2015;34:2317-2324
34. Zeng G, Xun W, Wei K, Yang Y, Shen H. MicroRNA-27a-3p regulates epithelial to mesenchymal transition via targeting YAP1 in oral squamous cell carcinoma cells. Oncol Rep. 2016;36:1475-1482
35. Bora-Singhal N, Nguyen J, Schaal C, Perumal D, Singh S, Coppola D. et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells. 2015;33:1705-1718
36. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J. 2012;31:2714-2736
37. Irvine KD. Integration of intercellular signaling through the Hippo pathway. Semin Cell Dev Biol. 2012;23:812-817
38. Wang Y, Pan P, Wang Z, Zhang Y, Xie P, Geng D. et al. β-catenin-mediated YAP signaling promotes human glioma growth. J Exp Clin Cancer Res. 2017;36:136
39. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI. et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23:5560-5567
40. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I. et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis. 2008;25:685-693
41. Wang D, Su L, Huang D, Zhang H, Shin DM, Chen ZG. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer. 2011;10:116
42. Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:287-292
43. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q. et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21:2580-2590
44. Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ. et al. Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;102:137-145
45. Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH. et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48:527-536
46. Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K. et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016;69:177-186
47. Straub M, Drecoll E, Pfarr N, Weichert W, Langer R, Hapfelmeier A. et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget. 2016;7:12024-12034
48. Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52:228-240
49. Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y. et al. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2017;8:114576-114587
50. Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH. et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491:493-499
51. Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW. et al. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. J Cell Mol Med. 2018;22:3139-3148
Corresponding author: Jie Zheng, PhD, Department of Pathology, Medical School of Southeast University, 87# Dingjiaqiao Road, Gulou Area, Nanjing 210009, PR, China. E-mail address: jiezheng54com; Tel: +86-25-83272507